Vick S, Cairns J, Urbaniak S, Whitfield C, Raafat A
Department of Management and Social Sciences, Queen Margaret College, Edinburgh.
Health Econ. 1996 Jul-Aug;5(4):319-28. doi: 10.1002/(SICI)1099-1050(199607)5:4<319::AID-HEC211>3.0.CO;2-6.
This paper estimates the incremental cost-effectiveness of providing antenatal anti-D prophylaxis in varying dose sizes to either primigravidae or all Rh D negative women. It presents a model for calculating the net cost per 1000 'at risk' women based on the costs of anti-D prophylaxis and the future NHS costs avoided. Incremental cost-effectiveness is measured in terms of the net cost per Rh D-alloimmunization and the net cost per Rh HD loss prevented. Programmes for Rh D negative primigravidae are more cost-effective than the same dose protocol extended to all Rh D negative women. The 1 x 1250 iu programme is the most cost-effective option.
本文评估了向初产妇或所有Rh D阴性女性提供不同剂量产前抗D预防的增量成本效益。它提出了一个基于抗D预防成本和未来避免的英国国家医疗服务体系（NHS）成本来计算每1000名“风险”女性净成本的模型。增量成本效益通过每例Rh D同种免疫的净成本和每例预防的Rh HD丢失的净成本来衡量。针对Rh D阴性初产妇的方案比将相同剂量方案扩展至所有Rh D阴性女性更具成本效益。1×1250国际单位方案是最具成本效益的选择。
